Key Takeaways
- Oracle shares have plummeted 24% across nine consecutive trading sessions—the company’s longest losing streak since December 2021.
- ORCL is trading 57% below its all-time closing peak of $345.72 reached on September 10, 2025.
- A remarkable 84% of Wall Street analysts maintain Buy ratings on ORCL, targeting an average price of $254.84.
- Concerns about Oracle’s aggressive capital spending and 3.21 debt-to-equity ratio are weighing on investor sentiment.
- Vice Chairman Jeffrey Henley liquidated $63.7 million in shares on June 24 through a pre-established trading arrangement.
Oracle (ORCL) shares commenced Friday’s session at $140.27, extending a prolonged descent that has alarmed shareholders even as Wall Street maintains historically bullish sentiment.
The database giant has witnessed nine consecutive sessions of decline, shedding 24% during this extended downturn. This marks ORCL’s most prolonged negative streak since late 2021.
The broader perspective reveals even deeper losses. After reaching a 2026 peak of $248.15 on June 1, Oracle has declined during 18 of the following 22 trading sessions. From its record closing high of $345.72 achieved on September 10, 2025, shares have surrendered 57% of their value.
The selloff appears particularly anomalous given sector dynamics. The iShares Expanded Tech-Software Sector ETF (IGV) has climbed more than 10% throughout the most recent five-day period. Oracle has charted the opposite trajectory.
Wall Street Maintains Conviction
The analyst community remains unfazed by the downturn. According to FactSet data, 84% of analysts covering ORCL maintain Buy recommendations—the highest concentration of bullish ratings in approximately two decades, excluding a brief spike in May 2011.
The consensus price objective stands at $254.84, suggesting roughly 82% appreciation potential from Thursday’s closing price.
Mizuho’s Siti Panigrahi maintains a $320 target and identifies Oracle as a top selection, emphasizing the company’s comprehensive AI capabilities spanning database, infrastructure, and application layers. KeyBanc’s analysts, maintaining a $300 target with an Overweight stance, indicated last month growing confidence that operating expense expansion will remain contained.
Piper Sandler elevated its price objective to $225 with an Overweight designation. Bank of America adjusted its target to $240 while maintaining a Buy rating. The aggregate consensus across 38 analysts registers a Moderate Buy with a mean target of $268.27.
Capital Spending and Leverage Concerns Dominate
Investor anxiety isn’t rooted in operational execution—Oracle actually surpassed Q4 expectations, delivering $2.11 earnings per share versus the $1.96 consensus estimate, on revenues of $19.18 billion, representing 20.6% year-over-year growth.
The apprehension centers on the financial requirements driving that performance. Oracle is deploying substantial capital toward AI infrastructure expansion, and Mizuho’s Panigrahi observed the enterprise will probably require external financing to support ongoing capex commitments. He identified “financing challenges” as a material risk factor.
The company’s debt-to-equity ratio currently registers at 3.21, a metric difficult for investors to overlook.
Oracle has additionally disclosed AI data center profitability uncertainties in regulatory submissions, intensifying market concerns about whether returns on the AI infrastructure buildout will materialize within investor expectations.
Vice Chairman Jeffrey Henley divested 400,000 ORCL shares on June 24 at a mean price of $159.16, generating proceeds of $63.7 million. The transaction occurred pursuant to a previously established Rule 10b5-1 trading arrangement and diminished his direct ownership position by 50%.
Oracle’s 52-week low sits at $134.57. With shares currently at $140.27, that technical support level looms nearby.


